ImmunoGen, Inc. Announces First Clinical Findings With Refined Dosing Strategy For IMGN853

WALTHAM, Mass. & SAN DIEGO--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Help employers find you! Check out all the jobs and post your resume.